BioAge Labs, Inc.
BioAge Labs, Inc. (BIOA): 5 pipeline candidates · 4 upcoming catalysts · ~47 mo cash runway. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
47.2 months
D/E 0.05 · 0% dilution
Lead: Phase 2
5 candidates
4 upcoming, next in ~196d
0 buys · 9 sells (180d)
A transparent, data-derived signal for BioAge Labs, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$887.1M
Cash
$241.8M
Quarterly Burn
$24.0M
Runway
47.2 mo
Revenue
$2.8M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| apj agonist antibody | Preclinical |
| apj agonist program | — |
| azelaprag | Phase 2 |
| BGE-102 | Phase 1 |
| nlrp3 program | — |
Upcoming Catalysts (4)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
142
Total value held
$484.1M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 4,188,540 | $73.2M |
| vanguard capital management llc | 2,709,812 | $47.4M |
| blackrock, inc. | 2,267,756 | $39.7M |
| ra capital management, l.p. | 1,650,648 | $28.9M |
| balyasny asset management l.p. | 1,327,545 | $23.2M |
| braidwell lp | 1,200,587 | $21.0M |
| polar capital holdings plc | 1,132,640 | $19.8M |
| state street corp | 850,894 | $14.9M |
| sands capital alternatives, llc | 786,353 | $13.8M |
| geode capital management, llc | 749,266 | $13.1M |
Showing top 10 of 142 institutional holders of BioAge Labs, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BioAge Labs, Inc.'s pipeline?
BioAge Labs, Inc. (BIOA) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BioAge Labs, Inc.'s lead drug candidate?
BioAge Labs, Inc.'s most advanced tracked candidate is apj agonist antibody (Preclinical) for Obesity.
What is BioAge Labs, Inc.'s next catalyst?
BioAge Labs, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: bge-102" — expected December 31, 2026.
What is BioAge Labs, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BioAge Labs, Inc. has approximately 47.2 months of cash runway.
What is BioAge Labs, Inc.'s market capitalization?
BioAge Labs, Inc.'s market capitalization is approximately $887.1M.
Get the full picture on BioAge Labs, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.